Research Article
The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus
Table 3
mMer and sMer levels in the presence or absence of manifestations in SLE with the studied parameters.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; mMer: membrane Mer tyrosine kinase; sMerTK: soluble Mer tyrosine kinase; MFI: mean fluorescence intensity; Anti-dsDNA Ab: anti-double strand DNA antibody; ACL: anticardiolipin antibody; AnuA: antinucleosome antibody; SSA: anti-SSA antibody; Sm: anti-Sm antibody; C3: Complement component 3; C4: Complement component 4. CRP: C-reactive protein. An independent Student’s -test was used for statistical comparison of mMer and sMer levels between the presence and absence of manifestations group in SLE. *, **, and ***. |